Vertex Pharmaceuticals Reports Phase 3 TRAFFIC/TRANSPORT Results for Orkambi in CF

Vertex Pharmaceuticals today announced results from the Phase 3 TRAFFIC and TRANSPORT trials evaluating Orkambi (lumacaftor/ivacaftor) in patients with cystic fibrosis who are homozygous for the F508del mutation. The trials met their primary endpoints, demonstrating significant improvements in ppFEV1 compared to placebo. These results led to FDA approval of Orkambi for CF patients homozygous for F508del.